Where is Lakshmijis ullu planning to fly?

‘liberation treatment’ for MS

Doctors at Fortis, Noida, treated a 60-year-old woman of multiple sclerosis (MS) — a disease of the nervous system that affects the brain and the spinal chord — using a new technique called ‘liberation treatment’.

The treatment, which is offered only in a few hospitals in the world, is based on the latest scientific research on MS that links deposition of harmful material in the brain — as is the case in MS — to narrowing of the veins carrying blood from the brain and the spine to heart.

“Shrinking of veins causes slower return of blood that results in accumulation of harmful substances such as iron in the brain and causes serious damage. In the ‘Liberation Treatment,’ we treat this narrowing of veins to ease the blood flow,” said Dr. Vikas Gupta, senior consultant, stroke and endovascular neurosurgery at the hospital, who led the team of doctors during the treatment.

................The treatment required a three-day stay in the hospital and cost around Rs 1.5 lakh.
(source: http://www.hindustantimes.com/New-treatment-for-multiple-sclerosis/Article1-554122.aspx

Fingolimod

http://www.ncbi.nlm.nih.gov/pubmed/19122034?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

http://www.webmd.com/multiple-sclerosis/news/20080416/good-news-for-oral-ms-drug-fingolimod?page=2
When you look at all the biologic treatments [medications that target the immune system to reduce the frequency and severity of attacks and reduce lesions within the brain] for MS, this 0.2% annualized relapse rate seems to be a new benchmark," Aradhye tells WebMD. "This was complemented by the encouraging observation that 89% of patients at year three have no evidence of inflammation in MRI brain scans [a sign of MS progression]."

Oral Drugs for MS

http://www.msakc.org/Articles/NoMoreNeedles.htm

Homeopathy

Dr S C Madan's phone number.011 29223344. He is a Homeopath in Delhi to have treated MS patients

http://abchomeopathy.com/forum2.php/1350/1

Gelesenium
Tarentula Hispana

OCT instead of MRI

Optical coherence tomography (OCT)

A five-minute eye exam might prove to be an inexpensive and effective way to gauge and track the debilitating neurological disease multiple sclerosis,

The retinal nerve fiber layer is the one part of the brain where nerve cells are not covered with the fat and protein sheathing called myelin, making this assessment specific for nerve damage as opposed to brain MRI changes, which reflect an array of different types of tissue processes in the brain.

Using OCT to scan the back of the eyeball, doctors can “see” the thickness of the nerve cells that extend from the optic nerve and become our retina.These cells are the only nerve cells in the central nervous system (CNS) which have no myelin covering.

“MRI is an imperfect tool that measures the result of many types of tissue loss rather than specifically nerve damage itself. With OCT we can see exactly how healthy these nerves are, potentially in advance of other symptoms.”

But MRI, aside from being expensive and uncomfortable, is often misleading since brain inflammation - also a symptom of the disease - can skew brain volume readings.

http://www.news-medical.net/?id=31252

http://blog.healthtalk.com/multiple-sclerosis/life-with-ms/optical-coherence-tomography-replacement-for-mri/

Optical coherence tomography (OCT) is a recently developed imaging technique that can generate cross-sectional images of tissue microstructure [9,10]. OCT is analogous to ultrasound, but measures the intensity of infrared light rather than sound

Lasik for MS patients

Lasik may build Intraocular pressure in MS patients
Some doctors are concerned that the increase in IOP during Lasik, All-Laser Lasik, and Epi-Lasik may be more problematic in MS patients. These doctors prefer LASEK, PRK, CK, RLE, P-IOL, or other procedures that do not require an increase in intraocular pressure.

The concern with Lasik and similar refractive surgery is that the body may respond to the surgical manipulation of the cornea in unexpected ways. Unexpected and unwanted responses are not consistent from disorder to disorder, nor are they consistent from patient to patient with the same disorder.

Although the FDA lists autoimmune disorders as a contraindication for laser eye surgery, doctors may perform the procedure if in their medical opinion the surgery is appropriate.If you have an autoimmune disorder you need to discuss this in detail with any prospective refractive surgeon, plus with your primary care physician and neurologist.

Read details on:
http://www.usaeyes.org/lasik/faq/lasik-multiple-sclerosis.htm


Night Vision Problems Caused By LASIK Eye Surgery
According to research studies conducted in recent years, several patients who underwent LASIK reported problems seeing at night. The induced night vision defects included halos, starbursts and glare around brightly lit objects at night. These night vision problems signify deterioration in quality rather than quantity of vision. Though these night vision problems are typically transient and wear off in a few days, in some patients, the symptoms might persist long after the eye heals.

http://www.healthguidance.org/entry/4088/1/Night-Vision-Problems-Caused-By-LASIK-Eye-Surgery.html

LASIK, which stands for laser in situ keratomileusis, was introduced in the mid-nineties and has largely replaced the older photorefractive keratectomy procedure, better known as PRK. Unlike PRK, where the surface layer of the cornea is scraped away to allow the reshaping of the underlying cornea, with LASIK a flap is made in the top cornea layer to permit access to the underlying cornea. LASIK avoids most of the problems of corneal haze, postoperative pain and slow rehabilitation seen in PRK, but complications are sometimes associated with the flap.

In LASEK (laser epithelial keratomileusis), the surface cornea layer is treated with alcohol and then peeled back to permit reshaping of the underlying layer. It avoids all flap-related complications associated with LASIK, and has less postoperative pain and faster recovery than PRK.

http://www.medicalnewstoday.com/articles/59689.php

Employers give reasonable Accomodations

Ada Forbes was a customer service representative. She was starting to have memory lapses when she was diagnosed with MS. She began treatment for the disorder, but was concerned about her ability to manage one of her accounts, so she asked her manager to assign someone else to the account. He refused. She later asked his boss and the HR manager, but no one would grant her an accommodation. Finally, as her performance deteriorated, she was fired.

She sued the company for discrimination under the Americans with Disabilities Act (ADA). The company argued that her claim was not valid because her condition didn't leave her limited in a major life activity, as the law stipulated. The question was whether memory and concentration are major life activities.

Uncertainty about what constitutes major life activity is a serious challenge to employers. In Ada's case, the courts ruled that ignoring Ada's request for accommodation and later firing her was a violation of the law, and ruled in her favor.

Companies should make use of their legal advisors in cases in which the law is not clear. Under ADA, an employer has a mandate to engage in a process with the employee to work out a reasonable accommodation.

Source :

http://www.swlearning.com/management/management_news/hr_0501_002.html

MS in the workplace

http://www.mult-sclerosis.org/news/Jan2003/MSintheWorkplace.html

One may find very useful info on the link above for suggested accommodations to be made by the employer for employees with MS. Such accommodations can include

• changing work hours to accommodate fatigue or allowing the employee to telecommute on some days
• reserved parking close to the building for an employee with mobility impairment, or, if that’s not possible, provide a motorized, portable scooter to get them from the parked car to the workplace.
• break rooms and bathrooms are accessible
• lunchroom microwave is within reach.
• And levers, rather than knobs, make opening doors and operating faucets easier for MS patients who may be suffering from poor coordination or numbness in body parts.

According to the National Multiple Sclerosis Society, employers also can:

• Allow an employee to use earned or unpaid leave for necessary treatment.
• Allow an employee to provide equipment or devices that the employer is not required to furnish.
• Adjust or modify examinations, training materials and policies.
• Buy or modify equipment or devices.

The study has shown that the prognosis is not as gloomy as is still widely believed.

http://occmed.oxfordjournals.org/cgi/content/abstract/31/4/134

The availability of sedentary work was as important as the amount of sickness absence in determining prospects for continued employment, and there was a more than even chance of remaining at work for as long as 15 or more years after diagnosis. Only one-third were registered as disabled persons; nearly half attended hospital for regular review, and of these, the majority were still employed. The study has shown that the prognosis is not as gloomy as is still widely believed.

Insurance against MS

http://www.icicilombard.com/app/ilom-en/Better-Life/Health.aspx?rssID=38605

Complementary & Alternative Medicine Law Blog

http://www.camlawblog.com/faqs-718-laws-governing-holistic-healing-some-basics.html

Employment Issues & MS

A Book By Phillip D.Rumrill, JR. Mary L. Hennessey, Steven W. Nissen


Excerpts & Review:

The authors discuss Priority employment concerns among people with MS in which the least dissatisfaction is on the access to social security programs. The highest dissatisfaction is on the adequate financial help to stay on job

Among people with MS who are unemployed; 75% left their jobs voluntarily, 80% feel they have ability to work & 75% wish to re-enter work. While 67-80% women with MS are unemployed, the ratio of unemployed men with MS is lesser going up to only 51-58% as per the National survey (depending upon variables like lesser education, working spouse and other physiological factors)

There are recommendations to enhance Work Performance :

The researchers emphasized the need to empower workers with MS to monitor the progression of their disease and request appropriate job modifications from their employers. Work enhancers like Job-adjustments, Environmental adjustments, & Assistive Technology, Social Support & Healthful self-care practices can improve work performance.

Well educated, professional level workers had fewer employment problems and consequently more optimism about their continued career success.

The respondents also say that Information concerning legal rights, health insurance, disability act, disability insurance would have helped them in retaining employment.Notably there are other issues than MS for people leaving jobs- 37% respondents give reasons of marriage, relocation, pregnancy, retirement.

Some recommendations for enhancing conditions and activities are: Sit-down job, planning tasks when energy levels are highest, adaptive devices, stress control, good night's sleep, peaceful atomosphere etc.

The strategy of least intervention may be the most sensible: Assist the person in retaining employment in the same job with the same employer or based on vocational analysis identify other roles.

The biggest advise is to not stop working or opt for unemployment for the well being/treatment to reduce stress for MS affected people. Unemployment may rather lead to additional stress. Make career planning a priority right from the start. While improvement in treatments have addressed to MS management issues, at the same time many employers have also started understanding about their obligations for reasonable accommodations.

Employers report that most workers with MS perform at levels equal to or higher than non-disabled employees.

The book is recommended for people with MS to build confidence, keep up optimism, and knowing their ABILITIES planning ahead in terms of career opportunities, alternate career, modifications or getting technology support. The book is especially helpful for people in US. MS is definitely challenging in terms of its unknown behavior but getting educated about it, knowing legal, consumer and employee rights helps planning and keep going.

Fingolimod for regulatory filing in 2nd half of 2009

FTY720 (fingolimod) directly reduces neurodegeneration and enhances repair of the central nervous system (CNS) damage caused by multiple sclerosis (MS) by interacting with sphingosine-1-phosphate receptors (S1P-R) expressed on brain cells. This mechanism of action may be in addition to the established anti-inflammatory role of FTY720 that is mediated by the reduction of inflammatory immune cells, called lymphocytes, from reaching the brain.

FTY720 is a novel, once-daily, oral treatment currently in worldwide Phase III clinical development to test its safety and efficacy as a disease modifying therapy for relapsing-remitting MS, which affects approximately 85% of people with multiple sclerosis.

"FTY720 crosses the blood-brain barrier and the drug's target S1P receptors are present on brain cells, including oligodendrocytes as shown in animal cell studies," said Jack Antel, Professor, Department of Neurology and Neurosurgery, McGill University, Montreal, Canada. "We are able to confirm that FTY720 directly modulates the S1P receptors on human oligodendrocyte progenitor cells."

FTY720 regulatory filing is planned for the second half of 2009.

Sourced from http://www.tecnogeeks.com/msviewsandrelatednews/blog5/index.php?itemid=751#more

fingolimod trial

http://fty720.blogspot.com/2007/08/fingolimod-facts.html

Dr. Bashir- Nebraska stem cell treatment

Dr. Bashir believes that a stem cell transplant will reset the patient’s immune system and reverse the disease five to 10 years, or to a better functioning state.

"This gives patients more time to live a productive life while slowing down the disease process. We hope to delay the onset of disability," Dr. Bashir said.

The use of stem cell transplantation to treat MS is not for every patient, Dr. Bashir warns.

"This is for a select few patients who have a very aggressive form of the disease. We want this treatment to keep patients, who are using a cane or walker, mobile," he said.

Internationally, 70 patients have completed this treatment. During a two-year follow-up, 40 percent of the patients have improved, 40 percent did not get worse and 20 percent either didn’t respond to the treatment or their disease progressed.

"This shows that in 80 percent of the patients, there is some possible benefit," he said.

The need in this area is great, Dr. Bashir said. Nebraska is in one of the highest endemic areas of the country for MS. There are an estimated 5,000 people with MS living within a 100-mile radius of Omaha.

About two years ago, Dr. Bashir opened an MS clinic at UNMC. He now sees 450 patients.

Fluxoetine shows promise

http://www.medscape.com/viewarticle/564301?src=mp

Fluoxetine, a selective serotonin reuptake inhibitor, was approved by the US Food and Drug Administration in 1987 and is frequently prescribed for the treatment of various psychiatric disorders, including major depression. However, fluoxetine also has a number of immunomodulatory effects, and previous studies have indicated that it might be beneficial for patients with MS, Dr. Mostert said in his presentation.

Previous research has also found that astrocytes in patients with MS lack beta-2 adrenergic receptors, and this leads to decreased cyclic adenosine monophosphate (cAMP) production, which in turn contributes to the initiation of the inflammatory cascade that eventually results in demyelination, Dr. Mostert explained. Because fluoxetine is able to increase the amount of cAMP in the astrocyte, the researchers hypothesized that the drug could help compensate for the loss of beta-2 adrenergic receptors and thus, reduce the amount of inflammation in MS.

Uric acid -cure for central nervous system diseases

Researchers at Rutgers University, New Jersey, have for the first time discovered that uric acid can play a crucial role in the treatment of spinal cord injury and other central nervous system disorders, such as stroke, multiple sclerosis, and Parkinson's disease.

"First there is the physical damage, but this is followed by secondary chemical damage to neurons [nerve cells] by compounds released in response to the trauma. We have found that uric acid can promote an early intervention step in combating this chemical damage through its action on astroglial cells," she added.

Astroglial cells or astrocytes are specialized cells that support neuron function with nutrients and protective buffering.

http://in.news.yahoo.com/070104/139/6atk5.html

OCT- Optical Coherence Tomography

A Johns Hopkins study has revealed that a five-minute eye exam might prove to be an inexpensive and effective way to gauge and track the debilitating neurological disease multiple sclerosis.

The new method can potentially complement costly magnetic resonance imaging (MRI) to detect brain shrinkage - a characteristic of the disease’s progression

The new study is based on a group of 40 multiple sclerosis (MS) patients, who used a process called optical coherence tomography (OCT) to scan the layers of nerve fibers of the retina in the back of the eye, which become the optic nerve.

OCT, which uses a desktop machine similar to a slit-lamp, is simple and painless. The retinal nerve fiber layer is the one part of the brain where nerve cells are not covered with the fat and protein sheathing called myelin, making this assessment specific for nerve damage as opposed to brain MRI changes, which reflect an array of different types of tissue processes in the brain.

http://news.sawf.org/Health/43743.aspx

Natco (Hyderabad) launches Generic drug Glatimer for MS

Natco Pharma Ltd announced the launch of Glatimer (Glatiramer acetate), a potent drug useful in the treatment of multiple sclerosis.

With this launch, Natco has become the first generic producer of this drug in the world, apart from being the first to introduce it in India, according to a company press release here on Wednesday. The branded version — called Copaxone from the global pharma major Teva Pharmaceuticals — has global sales of $1.8 billion. Incidentally, Glatimer will be a peptide chemistry-based product — the first one from among a series planned to be introduced by Natco in the coming years.

Natco has launched Glatimer at a MRP of Rs 28,500 for 30 vials. This is about 40 per cent of the price at which the innovator's brand is available. Natco expects that Glatimer would boost its revenues as well as profitability.

Multiple sclerosis is a disorder of the central nervous system and an estimated 2.5 million people in the world are affected by this disease. About 50,000 of them are in India, according to the company release.
http://www.thehindubusinessline.com/2007/05/17/stories/2007051702310200.htm

MS 1 in 700 in US

http://www.wrongdiagnosis.com/m/multiple_sclerosis/stats-country.htm#extrapwarning

Gene IL7R involved in Immune System

Dr. Margaret Pericak-Vance: "What we found is a gene that is called IL7R that's involved in the immune system. If you have a form of this, it increases your risk to get MS."

http://www1.wsvn.com/features/articles/medicalreports/MI56767/

Dr. Margaret Pericak-Vance
Miller School of Medicine
1120 NW 14 Street, CRB-819 (M-860)
Miami, FL 33136
305-243-2308
mpericak@med.miami.edu

National Multiple Sclerosis Society-South Florida Chapter
954-731-4224
305-599-0299
1-800-FIGHT MS (800-344-4867)
Fax: 954-739-1398
www.nationalmssociety.org/fls

DNA vaccine' for multiple sclerosis

DNA vaccine' for multiple sclerosis
13 Aug 2007

Scientists have reported that a newly developed DNA vaccine appears safe and may produce beneficial changes in the brains and immune systems of individuals with multiple sclerosis (MS).

The findings are reported in an article posted online that will appear in the October 2007 Archives of Neurology journal and refer to early tests carried out at the Montreal Neurological Institute with DNA vaccine BHT-3009.

The scientists will now continue to investigate the vaccine by carrying out a phase 2b trial - a randomised clinical trial in approximately 290 patients.

Alison Handford, Research Manager at the MS Society, said: “These are very early but encouraging findings and we welcome news that researchers are planning the phase 2b trial, which should hopefully yield positive results.”

Source:http://www.mssociety.org.uk/news_events/news/press_releases/dna_vaccine.html

Diappointing Beta-Interferon

03 Aug 2007

Authors of an article published in this week's edition of The Lancet medical journal claim a recent study has shown that early treatment with beta interferon reduced the risk for progression of disability by 40%.

"This paper concludes that early initiation of treatment with beta interferon prevents the development of disability after a three year follow up of a Betaferon trial, however the actual differences between those people treated early and those for whom treatment was delayed are very small.

"We await the results from the five year analysis from the BENEFIT study, but these results show small changes over a short time period and do not provide enough evidence that beta interferon delays disability progression in the longer term."

A statin a Day Keeps the Doctor Away

There is so much debate about statins possible role in curing so many diseases that it can be called as a Wonder Drug. While Statins are also known to have their own side effects too.

http://notw.typepad.com/hilary/2007/05/new_wonder_drug.html

By acting on the body's immune system, statins have been shown to soothe the painful inflammation caused by rheumatoid arthritis — and in a similar way they've been found to help prevent donor tissue rejection in kidney transplant patients.

In treating multiple sclerosis the drugs are being evaluated to see if they can stop immune cells moving from the bloodstream into the brain — which causes the relentless damage that leads to so much disability.

Even for cancer, doctors are hopeful. US researchers are using statins in harness with standard chemotherapy to see if they can stop breast cancer cells forming, growing or coming back. In other centres, statins are being assessed to treat cancer of the lymph gland system and lung cancer.

And asthma specialists in Canada have discovered an anti-inflammatory effect of statins on airways.

Versatile


So will statins really prove to be as versatile as eggs in the kitchen and aspirin in the pharmacy?

I think it's highly likely, although they certainly don't suit everybody— side-effects can include muscle pain and headaches. You also have to take them daily for life.

But millions already do. You can even buy a low dose of one type, simvastatin, over the counter.

Perhaps in future it will be a case of "a statin a day keeps the doctor away"

Multiple Sclerosis Sufferer Could Move Again After stem-Cell Treatment

Presently stem-cell treatment is banned in Britain, but a multiple sclerosis sufferer who went abroad for stem-cell treatment, can now move his hands and feet for the first time in years.

Rob Hodgson, from Elloughton near Hull, has been forced to use a wheelchair for the last 18 months and was unable to move the right side of his body. But he’s just returned from Rotterdam after undergoing experimental stem-cell treatment, where cells from umbilical cords are injected into the patient.

The MS society opposes the procedure even though it has helped some sufferers walk again. But Rob says he can’t believe the transformation. He raised nearly ten thousand pounds for the therapy, and says it’s the best money he’s ever spent.

Source:
http://stemcell.taragana.net/archive/multiple-sclerosis-sufferer-could-move-again-after-stem-cell-treatment/

Tibetan Medical Astrology centers

North Zone:

Men-Tsee-Khang



(Tibetan Medical & Astro Institute)
Branch Clinic, Middle Bakrota
P.O. Dalhousie-176304
Distt: Chamba
Himachal Pradesh
Tele:0091-1899-240814


Incharge: Dr. Kunsang Dolma Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Branch Clinic, Tibetan Settlement
P.O. Bhuppur-173025
Paonta Sahib, Distt: Sirmour
Himachal Pradesh
Tele: 0091-1704-223547


Incharge: Dr. Sonam Dorjee Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Branch Clinic, Block No.18/A
No.96/97, Main road, Kusumpti
Shimla-171009
Himachal Pradesh
Tele:0091-177- 2624504


Incharge: Dr. Jamyang Dolma
Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Branch Clinic Near Gunpa Road
P.O. Manali, Distt. Kullu
Himachal Pradesh
Tele: 0091-1902-251189 Incharge:


Dr. Kunchok Palzom Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Branch Clinic P.O. McLeod Ganj
Dharamsala-176219 Distt: Kangra
Himachal Pradesh
Tele: 0091-1892-221484


Incharge: Dr. Yeshi Dorjee Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Gangchen Kyishong
Dharamshala-176215
Distt: Kangra
Himachal Pradesh
Tele:0091-1892-222618(Ext.-218)


Incharge: Dr. Dawa Chodon
Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Branch Clinic P.O. Bir/Chowgan
Dist. Kangra-176077
Himachal Pradesh
Tele: 0091-1908-268370
Incharge: Dr. Pema Yangzom

Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Branch Clinic, P.O. Jispa
Tehsil: Keylong-175 132
Distt: Lahual/Spiti
Himachal Pradesh
Tele: 0091-1900-233205



Incharge: Dr.Lobsang Shakya
Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Branch Clinic, P.O. Choglamsar
Distt: Leh, Ladakh-194104
Jammu Kashmir
Tele:0091-01982-264409


Incharge: Lhugyal
Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Branch Clinic, 13,Jaipur Estate
East Nizamuddin
New Delhi-110013
Tele: 0091-11-24356503/24351099


Incharge: Dr. Tenzin Deche Kartsang Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Branch Clinic, New Camp House,
no:A-32, Majnu-ka-tilla
Delhi-110054
Tele: 0091-11-23817432/23816306


Incharge: Dr. Yeshi Khando Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
225, Rajpur Road, P.O.
Rajpur-248009, Distt: Dehradun
Uttaranchal
Tele:0091-135-2735383


Incharge: Dr. Lobsang Chonjor
Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Branch Clinic, Dekyiling Tibetan
Settlement, P.O. Kulhan-248001
Sahastrdhara Road
Distt: Dehra Dun
Uttaranchal
Tele: 0091-135-2607380


Incharge: Dr. Sonam Lhamo Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
A-15, Radha Garden Colony
Mawana Road, Ganga-Nagar
Meerut City-250001
Uttar Pradesh
Tele: 0091-121-2621177
Incharge: Dr. Lobsang Yeshi Men-Tsee-Khang
Dhang-lob


Incharge: Dr. Tenzin Khenrab
Men-Tsee-Khang
(TMAI-I)
Near Petrol Pump P.O & Distt. Leh Ladakh - 194101
J& K state
Tele:01982-253566/25354
Incharge: Dr. Kunchok Tsering


Men-Tsee-Khang
(Tibetan Medical & Astro Institute)
Ladakh Buddhist Vihar
Near ISBT
Bela Road
Delhi 54
Incharge:Dr.Tashi Tenzin.


Men-Tsee-Khang (Tibetan Medical & Astro Institute) Branch Clinic,Tibetan Settlement P.O. Bylakuppe-571104 Distt: Mysore
Karnataka State
Tele: 0091-821-694231


Incharge: Dr. Tenzin Tsephel Men-Tsee-Khang (Tibetan Medical & Astro Institute) Branch Clinic, No. 295, 5th Main Road, 11th Cross, Mahalakshmi Lay-out, (near Anjaneya Temple) Bangalore-560086
Karnataka State
Tele: 0091-080-3496190


Incharge: Dr. Dorjee Rabten Men-Tsee-khang (Tibetan Medical & Astro Institute) Branch Clinic, P.O. Gurupura-571188 Hunsur Taluk, Distt: Mysore
Karnataka State
Tele: 0091-0821-646071


Incharge: Dr. Tenzin Chokden
Men-Tsee-Khang (Tibetan Medical & Astro Institute) Branch Clinic, Camp No. 3, P.O. Tibetan Colony-581411 Mundgod, Distt: North Kannada
Karnataka State
Tele: 0091-08301-545716


Incharge: Dr. Kyizom Men-Tsee-Khang (Tibetan Medical & Astro Institute) Branch Clinic, Camp No. 6, P.O. Tibetan Colony-581411 Mundgod, Distt: North Kannada
Karnataka State
Tele:0091-08301-545071


Incharge: Dr. Thupten Gyaltsen Men-Tsee-Khang (Tibetan Medical & Astro Institute) Branch Clinic, P.O. Tibetan Colony Kollegal-571457 Distt. Chamarajnagar
Karnataka State
Tele: 0091-821-773297
Incharge: Dr. Tamdin Sangmo
Men-Tsee-Khang (Tibetan Medical & Astro Institute)
c/o Sermey Social Service, Sera Monastric University, P.O. Bylakuppe,
Distt.Mysore-571104
Karnataka State
Tele: 0091-0821-694752

Science of Stress and meditation

Stress: Forces from the outside world impinging on the individual. Stress is a normal part of life that can help us learn and grow. Conversely, stress can cause us significant problems.

Stress releases powerful neurochemicals and hormones that prepare us for action (to fight or flee). If we don't take action, the stress response can lead to health problems. Prolonged, uninterrupted, unexpected, and unmanageable stresses are the most damaging types of stress.

Stress can be best managed by regular exercise, meditation or other relaxation techniques, structured time outs, and learning new coping strategies to create predictability in our lives. The management of stress depend mainly on the willingness of a person to make the changes necessary for a healthy lifestyle.

First, the hypothalamus (a central part of the brain) releases a compound called corticotrophin releasing factor (CRF), which was discovered in 1981. The CRF then travels to the pituitary gland, where it triggers the release of a hormone, adrenocorticotrophic hormone (ACTH). ACTH is released into the bloodstream and causes the cortex of the adrenal gland to release the stress hormones, particularly cortisol, which is a corticosteroid hormone. Cortisol increases the availability of the body's fuel supply (carbohydrate, fat, and glucose), which is needed to respond to stress. However, if cortisol levels remain elevated for too long, then muscle breaks down, there is a decreased inflammatory response, and suppression of the immune (defense) system occurs.

Because they suppress the immune system, corticosteroids in measured doses are used to treat many illnesses that are characterized by inflammation or an overactive immune system, such as asthma and inflammatory bowel disease. For the same reason, they are used to help reduce the chances that our body will immunologically reject a transplanted organ. Corticosteroids also can cause fluid retention and high blood pressure. Therefore, it is critical that the response to corticosteroids be carefully controlled (modulated). This control usually is accomplished by a feedback mechanism in which increased cortisol levels feeding back to the hypothalamus and pituitary turn off production of ACTH. In addition, extremely high levels of cortisol can cause depression and psychosis, which disappear when the levels return to normal.

Exercise on a regular basis helps to turn down the production of stress hormones and neurochemicals. Thus, exercise can help avoid the damage to our health that prolonged stress can cause.
http://www.medicinenet.com/stress/index.htm

Myelin is 70% Lipids (cholesterol and phospholipid)

Myelin: The fatty substance that covers and protects nerves. Myelin is a layered tissue that sheathes the axons (nerve fibers). This sheath around the axon acts like a conduit in an electrical system, ensuring that messages sent by axons are not lost en route. It allows efficient conduction of action potentials down the axon. Myelin consists of 70% lipids ( cholesterol and phospholipid) and 30% proteins . It is produced by oligodendrocytes in the central nervous system .

So how do statins that lower cholesterol are believed to treat MS for good. Statins are supposed to have immunomodulatory role.

Statins: Miracles for Some, Menace for a Few

Statins have been hailed as miracle drugs for their ability to prevent deaths from heart attacks by lowering cholesterol. Some doctors go so far as to say the statins have had a greater effect on heart disease than anything else introduced in the last 50 years. Last year, a national group of experts issued guidelines saying statins should be prescribed to some 36 million Americans, three times as many as were taking them then, to reduce their risk of heart disease.

In addition to protecting people at high risk, statins protect people who have already suffered one heart attack. Three large studies have shown that statins reduce the risk of second heart attacks by 30 percent and the risk of death from second heart attacks by 40 percent.

There are also strong hints that statins may protect against strokes, Alzheimer's disease and osteoporosis and may perhaps one day be For useful in treating multiple sclerosis and other autoimmune diseases.

Given their apparent wide range of actions, statins have been called the modern-day equivalent of aspirin. Some experts have even suggested that they be sold over the counter.

But like aspirin and all other drugs, statins sometimes cause serious side effects. The most serious involves the muscles, a disorder called rhabdomyolysis, rare but debilitating and deadly if not detected in its early stages. Statins may also cause a liver disorder in about 1 percent of patients. Because of that, everyone taking them should have a periodic blood test to spot early signs of trouble.

The five statins now on the market are Lipitor (atorvastatin), Mevacor (lovastatin), Zocor (simvastatin), Pravachol (pravastatin) and Lescol (fluvastatin).

Statins should be stopped in anyone soon to have major surgery. Anyone experiencing muscle pain of unknown origin while taking statins should contact the doctor without delay. If a blood test shows a very high level of creatine kinase, the drug should be stopped immediately.

All patients taking statins should have periodic blood tests for the liver enzyme transaminase, which is elevated when the liver is being damaged.

For details visit
http://web.mit.edu/mwpstr/www/brody/

Exercise stimulates growth of new brain cells

Exercise stimulates the growth of new brain cells, a new study on rats finds. The new cells could be the key to why working out relieves depression.
ADVERTISEMENT

Previous research showed physical exercise can have antidepressant effects, but until now scientists didn’t fully understand how it worked.

Astrid Bjornebekk of the Karolinska Institute in Sweden and her colleagues studied rats that had been genetically tweaked to show depressive behaviors, plus a second group of control rats. For 30 days, some of the rats had free access to running wheels and others did not.

Then, to figure out if running turned the down-and-out rats into happy campers, the scientists used a standard “swim test.” They measured the amount of time the rats spent immobile in the water and the time they spent swimming around in active mode. When depressed, rats spend most of the time not moving.

“In the depressed rats, running had an antidepressant-like effect after running for 30 days,” Bjornebekk told LiveScience. The once-slothful rodents spent much more time in active swimming compared with the non-running depressed rats.

The researchers also examined the hippocampus region of the brain, involved in learning and memory. Neurons there increased dramatically in the depressed rats after wheel-running.

Past studies have found that the human brain’s hippocampus shrinks in depressed individuals, a phenomenon thought to cause some of the mental problems often linked with depression.

http://news.yahoo.com/s/livescience/20070628/sc_livescience/exercisegrowsnewbraincells

Natural Balance- Bhagvad Gita

If one affects the natural balance and harmony present in his body and sleeps or eats excessively, he will fail to preserve the equilibrium of the metabolic functions. Therefore, he will get sick and the cure to re-establish the balances in his organism is to be found in practicing yoga: "He who is temperate in his habits of eating, sleeping, working and recreation can mitigate all material pains by practicing the yoga system." (Bhagavad-gita 6.17)

Brahmi- Centella Asiatica

A recent study carried out by a researcher at the King's College, London, and Jadavpur University in Kolkata found that plants used in the ancient Ayurvedic therapy may be very efficient and successfully used in modern therapy, too. British and Indian scientists reported excellent results of Ayurvedic traditional herbs against symptoms which are common in Alzheimer's disease, such
as decline of mental abilities, poor memory and concentration etc.

Ayurvedic plants, including Brahmi, prevent the breakdown of neurotransmitter and also boost mental agility and the cognitive function. "However, it is too early to say that we have found a solution to Alzheimer's. That would be too tall a claim.We are just trying and all we can say is we are on the right track. There is a lot of difference between lab experiments and actual human applications. Only when we are able to reach the second stage can we claim we have reached somewhere. Also, we will have to consider the alternative manufacturing aspects," explained the executive council member of Jadavpur University, Partha Pratim Biswas.
http://news.softpedia.com/news/Ayurvedic-Plants-May-Be-the-Cure-for-Alzheimer-039-s-Disease-34904.shtml

The whole plant is alterative, cardio-depressant, hypotensive, weakly sedative and tonic[240]. It is a rejuvenating diuretic herb that clears toxins, reduces inflammations and fevers, improves healing and immunity, improves the memory and has a balancing effect on the nervous system[147, 152, 238, 240]. It has been suggested that regular use of the herb can rejuvenate the nervous system and it therefore deserves attention as a possible cure for a wide range of nervous disorders including multiple sclerosis
http://www.ibiblio.org/pfaf/cgi-bin/arr_html?Centella+asiatica

Facing the Brute;Neurophysiology-Meditation

Tremendous changes observed in the human brain and nervous system during mediation run contrary to this belief of 'passivity' attached to meditation. Unprecedented progress and research in neurobiology, investigative neurology, and study of neurotransmitters in the last two decades has given a great fillip to the study of neuro-physiology of Meditation and Yoga. Altered State of Consciousness can be brought about by hypnosis, drugs (e. g. LSD), sleep, etc.,

1) Yogis could slow both heart rate and rate of respiration,

2) Yogis could slow the rate of metabolism as confirmed by decreased oxygen consumption and carbon-di-oxide output.

3) Electro-Encephalo-Gram (EEG - recording of brain activity) in Yogis showed changes of calmness in the form of "alpha rhythm" during both eyes closed and eyes open recordings.

4) Their skin resistance to electric stimulation was increased (indicating increased tolerance to external stimuli).

Our usual 'defence-alarm' reaction to emotional and physical stress is in the form of "fright, flight, and fight" mediated through over-secretion of certain neuro-transmitters and neuro-modulators, namely adrenaline and dopamine by way of stimulation of sympathetic nervous system. Under the influence of these chemicals and hormones, we reflexively become panicky or aggressive, our blood pressure rises. Thus stress and anxiety is the end result if we allow our natural age-old sympathetic reactions to act and to come to surface. We try to run away, become fearful, or fight the situation. But today these 'defence-alarm' reactions have no place in our lives. Rather, they should be replaced by more calm and serene reactions of equanimity and fearlessness. The need is to just 'face the brute, and it will go away'. Such desirable reactions of non-aggression and peaceful attitude are generated by Yoga and meditation.

http://www.geocities.com/neovedanta/a28.html

unmet needs in MS treatment ;Rituximab,Fumaric Acid,FTY720,Statins

Medscape discussion with Dr. Waubant


There are, at this time, no predictors of how well a patient is going to do on first-line treatment; therefore, it takes a while before declaring treatment response or failure. Identifying early predictors of the response to available MS therapies would shorten the time of exposure to an unnecessary treatment that is doomed to fail.

Also, as all of the first-line treatments are injectable there is a need to develop medications that are available orally and/or that require less frequent administration, such as intravenous (IV) alemtuzumab (Campath) (once a year or less) and rituximab (once or twice a year). This would clearly enhance treatment compliance.

The long-term safety profile for the first-line therapies, such as beta-interferons and glatiramer acetate (Copaxone), is known and is actually very good. We have approximately 15 years of follow-up for these treatments if you include the clinical trials that were performed.

Finally, the side-effect profile of current first-line therapies, such as interferons, sometimes leads patients to discontinue treatment early. Therefore, there is a need for better tolerability of these long-term therapies.

One course of rituximab decreased by 90% the occurrence of new brain lesions between months 3 and 6 after first administration compared with placebo. Also, there was a reduction in relapse rate by month 6 that was over 50% compared with placebo. Overall, the medication is well tolerated over the short term.

There was another interesting study that investigated the effect of 0.3 mg and 0.6 mg of the oral drug laquinimod on MRI-monitored disease.[5] The study showed that there was a beneficial effect compared with placebo, especially at the high dose. There was a decrease of 51% in gadolinium-enhancing lesions at the 6-month mark and a decreased relapse rate with the high dose compared with placebo. The decrease was not statistically significant, but this may have to do with the relatively small size of the study.

If some of the ongoing phase 3 studies are positive, the drugs won't hit the market probably for 3 years or so. However, we are getting closer and that is very exciting. In addition to the phase 3 trials discussed earlier, there is another oral drug of interest, BG00012 or fumaric acid that is also in phase 3 trials. Results from a phase 2b extension study were presented and the drug was shown to be safe and tolerable.[9]

It is important to remember that all of these drugs have an unknown long-term side-effect profile, especially FTY720 and laquinimod, because they are not already on the market in other indications.

There were also a fair amount of presentations regarding potential mechanisms of action and the immune effects of different drugs in development for MS, such as FTY720 and statins. There has been a fair amount of interest in using statins as immunomodulating treatments for MS, but these trials are still ongoing.

http://www.medscape.com/viewarticle/557519?src=mp

Optical Coherence Tomography May Help Detect MS Disease Processes

Optical Coherence Tomography May Help Detect MS Disease Processes

Jacquelyn K. Beals


June 12, 2007 (Washington, DC) — Use of optical coherence tomography (OCT) to quantify retinal nerve fiber layer thickness (RNFLT) may offer advantages over MRI in detecting MS disease processes, a new study suggests.


"OCT is much quicker — it takes 5 minutes, as opposed to an hour to do an MRI. It's cheap compared with MRI, which is certainly costly," Dr. Grazioli told Medscape. "And it's looking as though it's going to be more specific for neural degeneration than MRI is." Dr. Grazioli noted that the MS community in general is exploring neural degeneration more than in the past, and that is where this new technique is heading.

http://www.medscape.com/viewarticle/558111?src=mp

Dr Klenner-High Protein Diet for Myelin; Vitamin B is imp

Dr. Klenner believed MS to have a viral cause. With a degree in Biochemistry he was able to understand what was happening in MS. The virus damaged the cells of the central nervous system rendering them incapable of maintaining homeostasis or normal metabolism by retaining adequate B1 within the cells, resulting in a deterioration of the myelin sheath surrounding the nerve and eventual paralysis. By raising the level of B1 in the body with a daily injection, a level could be maintained allowing normal metabolism to be continued, resulting in myelin sheath regeneration and recovery. In reality, MS is a deficiency disease caused by a viral inflammation of the central nervous system which can be reversed with adequate B1 and liver extract injections. Recovery can be enhanced with the addition of vitamins A, C, E, and B-complex and other metabolites in addition to a healthful diet and lifestyle.

I have followed this protocol for over 25 years. Following two severe attacks of MS in 1973 I could walk only a short distance and was forced to discontinue working — my doctors said I would be in a wheelchair soon. After beginning treatment with Dr. Klenner I was able to return to work within 6 months — but it was two years before I became symptom-free. I have enjoyed excellent health since.

The protocol of Dr. Klenner's I have followed consists of: (1) a daily intramuscular injection of vitamin B1 of 300 to 400 mg. The correct dosage can be determined by the level of fatigue the patient experiences. Some patients require 300 to 400 mg daily to experience relief of fatigue symptoms. The B1 is available in a strength of 200mg per ml. So a 200 mg injection would be 1cc. Twice weekly 1cc of liver extract is added to the B1 injection so extra injections aren't needed. The B1 injectable comes in a 30cc bottle and lasts for two to four weeks. The liver extract comes in a 10cc vial and lasts 5 weeks. The syringe is a 25 gauge by five-eighths inch 3cc syringe.

Note: B1 is not well absorbed in oral form — the daily injection is required for life for successful treatment and recovery.

Oral Vitamin Regimen
1. 5 grams daily in divided doses of Calcium Ascorbate (buffered Vitamin C) which is available in 500mg tablets. This boosts the immune system and eliminates or shortens recovery time from colds and flu.
2. Vitamin E 400 to 1000 IU daily
3. B-100 tablet. This tablet contains 100mg of all of the B vitamins.
4. B12 — One tablet (sublingual — dissolved under the tongue) daily. One to 2mg strength.
5. Niacin. Once or twice weekly, 100 to 300mg before breakfast. This is a vasodilator and opens the blood vessels allowing the nutrients to rebuild the myelin sheath damaged by MS. This will produce a flush and reddening of the skin for about 30 minutes, which most patients say they enjoy. It is advisable to lie down and cover up for the period of the flush.

Diet
A high protein diet is required to rebuild the myelin sheath. Examples: Breakfast — 1 or 2 eggs poached, with fruit and cereal. Lunch — fish and vegetables (steamed) and fruit. Supper — chicken or beef with vegetables and fruit. Soy, cheese and dairy products are a good source of protein if well tolerated.

One 500mg digestive enzyme tablet taken with each meal can often improve digestion and absorption.
http://www.townsendletter.com/Klenner/KlennerProtocol_forMS.pdf

Thyroid Hormone?

In a study published the Nov 16, 2004 issue of the Proceedings of the National Academy of Sciences, researchers reported on studies that looked at use of thyroid hormone as a potential treatment for multiple sclerosis. The animal studies found that thyroid hormone might protect against further nerve damage and facilitate more rapid repair of damaged nerve fibers.

In particular, use of thyroid hormone during early nerve damage could help protect the important myelin sheath -- the insulation that surrounds neurons -- and create precursor cells prepared to form new myelin sheaths in damaged nerves.

Loss of myelin is the key problem in multiple sclerosis According to the researchers: "We suggest that thyroid hormone could have a role in potentiating reluctant myelination by inducing (precursor cells) to differentiate into myelinating (cells) during a specific phase of the disease."

SOURCE: Fernandez, M.
http://thyroid.about.com/od/relatedconditions1/a/msthyroid.htm

Vitamin D through sun exposure and supplements

it is important to ensure that sufficient vitamin D (4000 IU/day) is acquired through sun exposure and supplements.


"It's pretty clear that when level of vitamin D Vitamins are too low, there's a greater tendency for cells that cause autoimmune problems to come out in those genetically susceptible people," says Cantorna "And it's pretty clear that taking supplemental vitamin D Vitamins is a good idea. You're hard-pressed to get enough vitamin D solely from food or from sunlight in the winter."

Other recent studies link a Vitamin D deficiency to a greater risk of other autoimmune disorders including rheumatoid arthritis, diabetes, unexplained muscle and joint pain, heart disease and various forms of cancer. As with MS and other autoimmune diseases, in which the immune system mistakenly attacks healthy tissue and organs in the body, the secret may be in how this nutrient affects cell activity.

Throughout most of the two million years of human development, humans had a relatively high intake of vitamin D (~5000-10,000 IU/day) from the sun. Major environmental changes brought on by the agricultural, industrial and technological revolutions have resulted in large populations in northern climates experiencing a subclinical and chronic vitamin D deficiency and this deficiency is more pronounced in persons with MS. Vitamin D deficiency is just one of a number of nutrient-related factors which play a role in MS.

More at the link below:
http://www.vitamin-d-max.com/vitamin-d-and-ms.html

Lifestyle recommendations

LIFESTYLE RECOMMENDATIONS

* Avoid stress and anxiety. They often precipitate attacks of MS.



* Avoid exposure to heat such as hot baths, showers, sunbathing and overly warm surroundings; avoid becoming overheated when working or exercising; and avoid exhaustion and viral infections. They all may trigger an attack or worsen symptoms.



* Get regular exercise and keep mentally active. These are extremely helpful in maintaining muscle function and bring about remission of symptoms. Exercises that increase body temperature can make the symptoms worse. Swimming is the best exercise but be wary cleanliness and avoiding infections. Stretching exercises are helpful.



* When an exacerbation begins, take at least two days of complete bed rest. This can often stop a mild attack.



* Maintain a strong immune system to avoid infections which often proceed the onset of MS. Avoid being around persons who have viral infections. Avoid getting chilled. Treat all infections promptly.



* Treatments to reduce Candida activity have been found to reduce the fatigue experienced by many people with MS.



* Utilize practices that evoke spiritual rejuvenation such as meditation, yoga, qi gong, tai chi and prayer.

Read more about Diet and Nutrition on the following link
http://www.compassionateacupuncture.com/Multiple%20Sclerosis.htm#RECOMMENDED%20%20FOODS

Take Nutrition, Supplements, Vitamins; Avoid allergens

Homer
Make MS history! After 10 years(!) I'm dealing with MS away from drugs just with nutrition, supplements, vitamins and a whole new way of life!

Inspiring blogs and website, how a person with MS decides to take charge of his life and

http://www.mymultiplesclerosis.gr/my_nutrition.html

Most common allergens found with Westerners with MS are dairy and gluten. Apart from that people be a little cautious with Soy, Capsicum,Eggplant, Artichokes.
Not many Indians have written about any such things.

Glucosamine-like supplement inhibits multiple sclerosis

A glucosamine-like dietary supplement has been found to suppress the damaging autoimmune response seen in multiple sclerosis and type-1 diabetes mellitus, according to University of California, Irvine health sciences researchers.
In studies on mice, Dr. Michael Demetriou and colleagues with the UC Irvine Center for Immunology found that N-acetylglucosamine (GlcNAc), which is similar but more effective than the widely available glucosamine, inhibited the growth and function of abnormal T-cells that incorrectly direct the immune system to attack specific tissues in the body, such as brain myelin in MS and insulin-producing cells of the pancreas in diabetes. Study results appear on the online version of the Journal of Biological Chemistry.

“This finding shows the potential of using a dietary supplement to help treat autoimmune diseases,” said Demetriou, an assistant professor of neurology, and microbiology and molecular genetics. “Most importantly, we understand how this sugar-based supplement inhibits the cells that attack the body, making metabolic therapy a rational approach to prevent or treat these debilitating diseases.”

http://www.physorg.com/news98368825.html

MS India: MS US

Neurology. 1996 Feb;46(2):385-7. Related Articles, Links

Comparison between multiple sclerosis in India and the United States: a case-control study.

Bansil S, Singhal BS, Ahuja GK, Ladiwala U, Behari M, Friede R, Cook SD.

Department of Neurosciences, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA.

The prevalence of MS in India is low, and it is unclear whether the manifestations of the disease in India are similar to the United States. We carried out a case-control study to compare the disease in the two populations and used clinical, evoked potential, and MRI criteria to assess similarities and differences. Our results indicate that the rate of disease progression and frequency of involvement of the cerebral hemispheres, cerebellum, spinal cord, and brainstem were similar in the two populations. The visual system was more frequently involved in Indian patients. No Indian patient had a family history of MS; this suggests an environmental disease-triggering agent.

PMID: 8614499 [PubMed - indexed for MEDLINE]

Kathy's travel to India

Kathy was diagnosed with relapsing-remitting MS in 1987, when she and her husband, Dave, were in the process of adopting a child from India. They decided to continue and were soon the proud parents of a 4-month-old boy. In 1991 we adopted again, they adopted a 13-month-old girl, Julia, also from India.

"We had always vowed that when Jeremy and Julia were old enough, we would take them back to see the country. Over the years we have become active in the Indian community in Denver, and in 2004, one of the families proposed to play tour guide for a group visit
.........

I am very blessed to have family and friends who supported me all the way. I think I surprised everyone, including myself, as I discovered how much I could handle. I learned to adapt to whatever happened, to keep my sense of humor, and to treat everything as an adventure."

Kathy Evans has had MS since 1987. She, Dave, Jeremy, and Julia live in Denver, Colorado.

Her experience in India
http://findarticles.com/p/articles/mi_m0850/is_2_24/ai_n17093733

ABILITY is the Word

Bill Gates, Renowned for his company Microsoft, Gates is legally blind.

In North America and most of Europe, legal blindness is defined as visual acuity (vision) of 20/200 (6/60) or less in the better eye with best correction possible. This means that a legally blind individual would have to stand 20 feet (6 m) from an object to see it with the same degree of clarity as a normally sighted person could from 200 feet (60 m).

Montel Williams, famous American talk show host on television, recently announced he has a type of Multiple Sclerosis. He continues his weekly talk show.

Tom Cruise, Hollywood movie star, he has dyslexia. He has yet to be able to read a film script, yet performs beautifully in many various roles.
Dyslexia is most commonly characterized by difficulties with decoding written text or with achieving accuracy and fluency in reading, and by poor spelling. Dyslexic individuals may also reverse or transpose letters when writing or confuse letters such as b, d, p, q, especially in childhood. However, dyslexia is not a visual problem that involves reading letters or words backwards or upside down, nor are such reversals a defining characteristic of dyslexia.

Many individuals with dyslexic symptoms involving reading, writing, and spelling, also have common shared symptoms such as poor short-term memory skills, poor personal organizational skills, problems processing spoken language, left-right confusion, difficulties with numeracy or arithmetic, and issues with balance and co-ordination.

Source:http://www.wapd.org/news/021103.html
& wikipedia

Sunlight Vitamin D : Dark skinned people don't absorb easily

Vitamin D may fight multiple sclerosis
by Lindsey Tanner, AP Medical Writer

The Associated Press Translate This Article
20 December 2006

CHICAGO (AP) - An abundance of vitamin D seems to help prevent multiple sclerosis, according to a study in more than 7 million people that offers some of the strongest evidence yet of the power of the ``sunshine vitamin'' against MS.

The research found that white members of the U.S. military with the highest blood levels of vitamin D were 62 percent less likely to develop multiple sclerosis than people with low levels.

There was no such connection in blacks or Hispanics, possibly because there were so few in the group studied. Also, the body makes vitamin D from sunlight, and the pigmented skin of blacks and other dark-skinned ethnic groups doesn't absorb sunlight as easily as pale skin.
http://www.globalgoodnews.com/health-news-a.html?art=116661714310080937

Revimmune: " Rebooting" the Immune System

Accentia Biopharmaceuticals acquires worldwide exclusive license to Revimmune

This is an amazing sounding treatment, but bear in mind that it is still in late-stage development. Revimmune attempts to treat and potentially cure autoimmune diseases such as MS by “rebooting” the human immune system, and the rights to sell this compound have been acquired by Accentia Biopharmaceuticals (Nasdaq: ABPI). According to a press release linked below, the drug works by decimating peripheral immune cells, including those responsible for autoimmune responses like MS. Stem cells located in the bone marrow are spared however, and they reconstitute the immune system over a period of 2 to 3 weeks. Typically the reconstituted system lacks the misdirected autoimmunity, resulting in a reduction or elimination of disease progression. While MS will be Accentia’s lead indication for Revimmune, the article mentions many other autoimmune diseases including systemic lupus, juvenile diabetes mellitus, rheumatoid arthritis, Crohn’s disease, myasthenia gravis, and scleroderma.

http://brainspotting.org/

http://brainspotting.org/

A blog about multiple sclerosis news and current events

BBIC- soy based inhibitor

Bowmann-Birk Inhibitor Concentrate (BBIC) from Soy May Help Treat Multiple Sclerosis
Filed in archive Drugs, Vaccines and Therapeutics , Food and Agriculture by ruth on December 14, 2006
Soybeanvarieties.jpg
A preparation from soy called Bowmann-Birk Inhibitor Concentrate (BBIC) appears to dramatically improve mobility and walking of an animal model with multiple sclerosis, and neurologists say that the substance may be useful as a single therapy, or in conjunction with conventional therapies used in treating MS, such as beta-interferon.

Further analysis revealed that the central nervous systems of animals that received BBIC showed "significantly less inflammation and demyelination" than those that didn't receive the therapy. "It's the first time that BBIC has been used in an EAE model and has shown significant disease suppression, and we hope it can eventually be used in humans," says Dr. Rostami. His group's next step is to design clinical trials in humans.

The researchers speculate that BBIC works by suppressing the immune response to some extent, or by inhibiting proteases responsible for the inflammation and demyelination in MS. They study has been published in the journal Multiple Sclerosis.

http://www.biotech-weblog.com/50226711/bowmannbirk_inhibitor_concentrate_bbic_from_soy_may_help_treat_multiple_sclerosis.php

BBIC – A SOY-based Substance Treats Multiple Sclerosis

BBIC – A SOY-based Substance Treats Multiple Sclerosis
Health News Posted on December 17, 2006

Bowmann-Birk Inhibitor Concentrate (BBIC) is a natural soy-based substance. A US based study finds: BBIC improves the condition of animals with a disease similar to multiple sclerosis.


A group of animals with Autoimmune Encephalomyelitis (EAE) received BBIC, while another group of animals also suffering from the same disease received a placebo.

"Animals that received BBIC were able to walk, while those that didn't get the drug were not," said the study leader Dr. A.M. Rostami, professor and chairperson of the department of Neurology at Jefferson Medical College in Philadelphia.

The animals that received BBIC were able to walk though with some limp or weakness. Although they were’nt completely cured, the results are promising, the researchers said.

It was also found that the CNS of the animals that received BBIC had "significantly less inflammation and demyelination" than animals that hadn't received BBIC.

"It's the first time that BBIC has been used in an EAE model and has shown significant disease suppression, and we hope it can eventually be used in humans," Rostami said.

BBIC inhibits secretion of Proteases, a group of enzymes that are responsible for the inflammation and demyelination associated with multiple sclerosis (MS), a condition which causes inflammation in the myelin coating of nerve fibers.

Source-Medindia
PRI
http://www.medindia.com/news/view_news_main.asp?x=16774

Fingolimod in 2009

showed that disease activity, measured by magnetic resonance imaging or MRI, was reduced by up to 80% compared to placebo, and the rate of relapses dropped by 50%. Patients who continued fingolimod in the following six months maintained the lowered relapse rate, and patients who were switched from placebo to fingolimod dropped their relapse rate by at least 70%.

"These results demonstrate that once-daily oral FTY720 provides a significant and rapid improvement in MRI measures of inflammation, as well as in relapse-related clinical endpoints in patients with relapsing multiple sclerosis," said Chief Investigator Professor Ludwig Kappos, MD, of the Department of Neurology at the University Hospital in Basel, Switzerland. "If the magnitude of benefits shown in this Phase II study are confirmed in the larger-scale Phase III study program, oral FTY720 could represent a major improvement in the way MS will be treated in the future."

Of paramount concern after the Tysabri-PML situation, the safety profile of FTY720 seems relatively mild at this stage (recall that so did Tysabri's when it was in Phase II and III). Most common adverse affects had to to do with respiratory infections and GI issues. There were also increases in liver enzyme activity and blood pressure, though these were asymptomatic. A close eye will certainly be kept on these parameters during Phase III.

Speaking of which, the Phase III study, called FREEDOMS, is massive. It includes over 100 study centers and will ultimately enroll over 2,000 patients worldwide in a 2 year trial.

Yes, 2 years and "currently enrolling" means that the minimum time to market for Fingolimod should be approximately 3 years from now, placing us in 2009. Certainly, this tempers the excitement about this drug for the time being, but it is always encouraging to see a promising therapy progressing to the final stage of trials-- and in this case, potentially delivering the benefit of a once-daily oral therapy with a limited side effect profile and potent disease modifying abilities.
http://www.thisisms.com/article280.html

Once-a-day pill

Issue: May 2007
Internal Medicine World Report

First Once-Daily Oral Therapy Promising Option for Relapsing MS

by Maude Campbell

CHICAGO—The first once-daily oral therapy for the treatment of relapsing multiple sclerosis (MS) has shown promising results in a 2-year study. Patients receiving the investigational drug fingolimod (Novartis), a sphingosine-1-phosphate receptor modulator, maintained low disease activity and had a reduced risk for relapse, reported Ludwig Kappos, MD, at the American Neurological Association annual meeting.

Unlike current MS treatments that require frequent injections, “Fingolimod is given conveniently in the form of a once-daily pill,” said Dr Kappos, of the Departments of Neurology and Research, University Hospital, Basel, Switzerland.

The study included 281 patients with relapsing MS who were initially randomized to 1.25 or 5 mg of fingolimod once daily or to placebo. After 6 months of treatment, the median number of gadolinium-enhanced lesions seen on magnetic resonance imaging (MRI) was significantly lower in patients receiving fingolimod than in the placebo group. In addition, the annualized relapse rate was 55% lower in the low-dose fingolimod group and 53% lower in the high-dose group compared with placebo. The study was also published in the New England Journal of Medicine (2006; 355: 1124-1140).

A total of 227 patients were then enrolled in an extension phase, during which the original placebo patients were rerandomized to 1 of the 2 fingolimod doses. The median number of lesions on MRI remained low, and relapse rates continued to decline with the active treatment, Dr Kappos said.

At the end of 2 years, among those who continuously took fingolimod, 87% of the 5-mg group and 81% of the 1.25-mg group were free of lesions on MRI; and 74% and 72%, respectively, had no MS relapses.

Among the original placebo patients, 91% of those switched to high-dose fingolimod and 79% of the low-dose treatment recipients remained free of new lesions; 24% of patients in both groups had no relapses.

“The results are promising and, if confirmed by phase 3 data, fingolimod could contribute significantly to improving the quality of life of patients with relapsing MS,” Dr Kappos said.

Source :http://www.imwr.com/issues/articles/2007-05_36.asp

Oral Cladribine

Phase III Trial Of Oral Cladribine, A Novel Investigational Therapy For Multiple Sclerosis, Begins In The United States
Main Category: Multiple Sclerosis News
Article Date: 05 May 2006 - 0:00 PDT
| email to a friend | printer friendly | view or write opinions |
Article Also Appears In

* Clinical Trials / Drug Trials


sign up to our weekly newsletter
Sign up for news alerts

rate this article



Serono (drt-x: SEO and NYSE: SRA) announced today that recruitment in the U.S. is beginning for the Phase III CLARITY study (CLAdRIbine Tablets in Treating MS OrallY Study) of oral cladribine for the treatment of patients with relapsing forms of multiple sclerosis (MS). This multi-national study was successfully initiated outside the U.S. in 2005, and will now expand to include 17 clinical trial sites in the U.S. The study is one of the largest MS trials ever conducted, and enrollment is on track to be completed in 2006.

CLARITY is a two-year, double-blind, placebo-controlled Phase III study of more than 1,200 patients. It is designed to assess patients' clinical relapses, disability progression and MRI (magnetic resonance imaging) brain activity. Previous clinical trials using cladribine administered by injection in patients with MS showed positive effects in reduction of new lesion development in the brain as seen on MRI scans; reductions in relapses were also observed.

"The Phase III CLARITY trial is enrolling at a strong pace, and the addition of US sites will accelerate this pace and bring us one step closer to our goal of making the first oral MS therapy available for people living with this debilitating condition, underscoring our fundamental and long-term commitment to the MS community," said Dr. Paul Lammers, Chief Medical Officer at Serono, Inc. "The formulation of oral cladribine, combined with the proposed short dosing regimen, should help patients to be more compliant with their MS therapy and lighten the patient's treatment burden associated with chronic MS."

"We all are looking forward to the day when there is an FDA approved oral therapy that can affect the underlying disease process in MS," said Dr. John Richert vice president research and clinical programs at the National MS Society. "Clinical studies, such as CLARITY, are an important part of the process leading to the development of these new medications. Those interested in determining whether they are eligible to participate in the clinical trial should speak with their healthcare provider."

Husbands and wives living with multiple sclerosis

By McNeal, Linda J.
Publication: Journal of Neuroscience Nursing
Date: Feb 2005
Multiple sclerosis (MS) frequently is diagnosed in young adults. Coping with symptoms of MS is challenging not only for the person with the disease, but also for his or her spouse. The well spouse often assumes the caregiving role.

People expect to become caregivers for babies, children, and elderly parents. They do not, however, expect to become caregivers for a chronically ill spouse at a time when they are focusing on developing a career, providing for their family, and caring for their children. Thus, spousal caregivers of people with multiple sclerosis (MS) face unique challenges and demands. With its physical, social, and psychosocial effects, this disease permeates all aspects of family life (Artinian, 2001; Holland, 2003; Weihs, Fisher, & Baird, 2002).

MS is unpredictable and symptoms vary, even among those with the same type of MS. The psychological and emotional aspects of MS and the uncertainty regarding symptoms and prognosis are challenging to patients and family members (Coleman, Rath, & Carey, 2001). MS demands flexibility. During periods of exacerbation, the family must quickly mobilize resources and move into crisis mode (Patterson & Garwick, 1994). Invisible symptoms of MS (e.g., visual and sensory losses, fatigue) can confuse family caregivers. For example, debilitating fatigue, which is characterized by a lack of energy that is worse in the afternoon and evening, can occur suddenly (Kaplan, 1999) and may be hard for a spouse to understand and appreciate.

MS does not alter normal family developmental stages but rather adds new demands and challenges. For example, child care does not stop when one parent has an exacerbation; thus, the well parent often adds child care responsibilities to his or her other chores. Caregiving partners experience fear of an uncertain future, social disruption, financial difficulties, and isolation (Rees, O'Boyle, & MacDonagh, 2001).

Spouses are expected to provide support while needing support. They, too, experience numerous losses: role and relationship changes, and possible career and financial changes if their wives or husbands had been employed. These stressors can lead to ineffective serf-care for the wife or husband; the reciprocal effects of illness can create enduring strain for partners (Kuyper & Wester, 1998; Pakenham, 2001). Indeed, the effects of MS ripple through the family, with each person's reaction affecting other family members.

Patients frequently have fluctuating symptoms. Spouses attempt to make sense of the nebulous symptoms while trying to be supportive and continuing their normal routines. The time from first awareness of symptoms to diagnosis can be long, frustrating, and confusing. The waiting and wondering, with unrewarding and untherapeutic encounters with healthcare professionals, can lead to feelings of powerlessness and loss of a sense of control for people with MS and their spouses (Courts, Buchanan, & Werstlein, 2004).

The wives also were advocates for mental health treatment and quality-of-life concerns. One wife, seeking help for her husband's depression after the MS diagnosis, described their experience with a counselor as follows:

[W]hat we got wasn't primarily about MS or
dealing with disease-induced depression, which
is different from clinical depression, which is different
from grief depression. We got a talk and an
offer of more pills ... so I think ... what he would
like the best for both of us, is just some genuine
support ... because taking the pills ... isn't the
only answer.

Husbands expressed the need for friends and family to know more about MS, too. One husband said "The biggest thing ... or problem is the public view of MS ... for my family, her family, and friends to know exactly what this is." Another husband stated, "The greatest problem that she's had ... is outsiders understanding this, and even her own parents don't really comprehend how difficult it is for her." They experience resentment from friends. According to one focus group participant, a friend said "'We're always coming to your house. You don't ever come to ours'."

http://www.allbusiness.com/health-care-social-assistance/nursing-residential/518268-1.html

Testosterone 'helps men fight MS'

From correspondents in Washington

May 16, 2007 02:05am
Article from: Agence France-Presse


TESTOSTERONE, the mighty hormone that elevates physical energy and sex drive, can also help fight the effects in men of multiple sclerosis, which weakens the body's immune and nervous systems.

Nancy Sicotte of the University of California-Los Angeles and a team of researchers found in a small pilot study on ten men with MS that regular application of a gel containing testosterone helped their cognitive ability and retarded brain deterioration characteristic of MS.

The ten subjects, each with relapsing-remitting MS - in which the disease generates periodic neurological symptoms like numbness and difficulty moving around, and then falls into periods of remission - were given daily applications of the gel, containing 100 milligrams of testosterone, over 12 months.

Before the treatment the subjects, who averaged 46 years old, showed on average an annual decrease in brain size due to MS of 0.81 per cent. But after receiving the testosterone, brain atrophy slowed to 0.25 per cent a year.

In addition, the participants enjoyed on average a 1.7 kilogram increase in muscle mass during the treatment, and reported no adverse effects.

“One year of treatment with testosterone gel was associated with improvement in cognitive performance and a slowing of brain atrophy (deterioration),” the authors of the study wrote in a summary of their research released yesterday.

“Overall, in this first trial of testosterone treatment in men with relapsing-remitting MS, the treatment was shown to be safe and well tolerated.”

They also said that the successful use of testosterone to fight brain atrophy in men with MS suggests the same treatment might work with other non-inflammatory neurodegenerative diseases like ALS - amyotrophic lateral sclerosis, or Lou Gehrig's disease.

The study was published in the May issue of Archives of Neurology.
http://www.news.com.au/story/0,23599,21740352-1702,00.html

MS awareness in India

Charities join forces to improve multiple sclerosis awareness in India


From the MS Society, Jane Petty, National Physiotherapy Lead, Alison Handford, Research Manager and Caron Furnival, Head of Service Development will offer their expertise.

Caron said: “India is way behind the UK in terms of access to services and education. There are only 4,000 known cases of MS in India but it is estimated that there are probably between 40,000 and 50,000 people affected by the condition.

http://ms-in-india.blogspot.com/2007/01/charities-join-forces-to-improve.html

MS in India

Multiple sclerosis in India: a case-control study of environmental exposures.

Original Articles
Acta Neurologica Scandinavica. 95(2):90-95, February 1997.
Bansil, S. 1; Singhal, B. S. 2; Ahuja, G. K. 3; Riise, T. 4; Ladiwala, U. 2; Behari, M. 3; Cook, S. D. 1

Abstract:
Objectives: To compare the rate of prior environmental exposures between Indian multiple sclerosis (MS) patients and controls in order to identify potential disease triggering factors.

Material and methods: A standard self-administered questionnaire regarding prior exposures was presented to 56 Indian MS patients and 147 other neural disease and healthy controls at two large medical centers in India.

Results: The rate of prior foreign travel, surgeries, blood transfusions, clinical chicken pox and mumps infections and exposure to cats and farm animals was not significantly different between MS patients and controls. However, clinical measles infection and dog exposure occurred significantly more often in the MS patients.

Conclusion: These findings are consistent with but do not prove an association between prior measles infection, dog exposure and MS.

(C) 1997 Munksgaard International Publishers Ltd.
http://pt.wkhealth.com/pt/re/obes/abstract.00000132-199702000-00005.htm;jsessionid=GmWZLh2sb2rgdy1z1f4RkCdhgTQL771tPLJ8Q9NC3LhYTJkgcrMB!-1804036389!-949856145!8091!-1

Remyelination can be extensive in multiple sclerosis despite a long disease course.

Remyelination can be extensive in multiple sclerosis despite a long disease course.

* Patani R,
* Balaratnam M,
* Vora A,
* Reynolds R.

Department of Cellular and Molecular Neuroscience, UK MS Tissue Bank, Division of Neuroscience, Imperial College London, Charing Cross Hospital Campus, London, UK.

Experimental studies using models of multiple sclerosis (MS) indicate that rapid and extensive remyelination of inflammatory demyelinated lesions is not only possible, but is the normal situation. The presence of completely remyelinated MS lesions has been noted in numerous studies and routine limited sampling of post mortem MS material suggests that remyelination may be extensive in the early stages but eventually fails. However, visual macroscopic guided sampling tends to be biased towards chronic demyelinated lesions. Here we have extensively sampled cerebral tissue from two MS cases to investigate the true extent of remyelination. Sections were cut from 185 cerebral tissue blocks and stained with haematoxylin and eosin (H&E), luxol fast blue and cresyl fast violet (LFB/CFV) and anti-myelin oligodendrocyte glycoprotein, human leucocyte antigen-DR (HLA-DR) and 200 kDa neurofilament protein antibodies. Demyelinated areas were identified in 141 blocks, comprising both white matter (WMLs) and/or grey matter lesions. In total, 168 WMLs were identified, 22% of which were shadow plaques, 73% were partially remyelinated and only 5% were completely demyelinated. The average extent of lesion remyelination for all WMLs investigated was 47%. Increased density of HLA-DR(+) macrophages and microglia at the lesion border correlated significantly with more extensive remyelination. Results from this study of two patients with long standing disease suggest that remyelination in MS may be more extensive than previously though

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17442065&query_hl=9&itool=pubmed_docsum

Positive results... testosterone for men with MS

Positive results published on testosterone for men with MS

Researchers from the University of California, Los Angeles have published results from a small study, funded by the US National MS Society and others, suggesting that one year of treatment with a gel containing the sex hormone testosterone (applied to the skin) in 10 men with relapsing-remitting multiple sclerosis resulted in significant improvements in cognitive function and in slowing brain tissue loss.

Nancy Sicotte, MD, Rhonda Voskuhl, MD, and colleagues report these positive findings in the May 2007 issue of Archives of Neurology (2007;64:683-688).

http://www.msif.org/en/global_ms_network/ms_news/positive_results.html

Progesterone & Testosterones for MS :-)

While women experiencing complete remission during pregnancy prompted researchers to come up with Progesterone creams or pills for women. The same exciting results are observed with male testosterone!

Researchers from the University of California, Los Angeles have published results from a small study, funded by the National MS Society and others, suggesting that one year of treatment with a gel containing the sex hormone testosterone (applied to the skin) in 10 men with relapsing-remitting multiple sclerosis resulted in significant improvements in cognitive function and in slowing brain tissue loss. Nancy Sicotte, MD, Rhonda Voskuhl, MD, and colleagues report these positive findings in the May 2007 issue of Archives of Neurology (2007;64:683-688).

This small study shows that testosterone treatment may have therapeutic benefit in men with relapsing-remitting MS. Further study involving larger numbers of patients and control groups is necessary to confirm these early results, and to ensure the safety and effectiveness of testosterone treatment for MS.

“We’re gratified that these early, promising results stemmed from the National MS Society’s targeting of gender differences as an important area of research in MS,” said Dr. John R. Richert, the Society’s executive vice president of research. “It also demonstrates how basic laboratory findings can quickly translate into possible new therapeutic strategies.”

Dr. Voskuhl and colleagues are already proceeding with a similar effort involving the sex hormone estriol: Based on a small, early-phase trial that showed decreases in disease activity in 12 women with MS, she is now launching a multicenter, controlled clinical trial of oral estriol (added to the approved MS therapy glatiramer acetate) in 130 women with relapsing-remitting MS.

Read more at:
http://www.nationalmssociety.org/site/PageServer?pagename=HOM_RES_research_2007may18

Bulletin May 11, 2007 MS Society

Progress on Experimental Therapies for MS, and Much More, Reported at the American Academy of Neurology Meeting

May 11, 2007

John Dystel Prize Presentation

“I do not think it is too bold to think about curing MS,” stated Dr. Howard Weiner winner of the 2007 John Dystel Prize for MS Research awarded by the National MS Society and the AAN during a presentation in which he talked about how far MS research had come since he started treating people with MS in 1972. “Enormous progress has been made.”

Experimental oral therapies:


· Dr. Giancarlo Comi (Scientific Institute and University Ospedale San Raffaele, Milan) and others administered 0.3 mg or 0.6 mg doses of oral laquinimod (Teva Pharmaceutical Industries, Ltd., Active Biotech AB) daily for 36 weeks to 306 people with RR MS. The primary goal was to determine if the immune-modulating drug would reduce the number of active MRI brain lesions. In those taking 0.6 mg, active lesions decreased significantly, by 38%, compared with the placebo group, but not in those on the lower dose. Participants tolerated both doses, experiencing transient increases in liver enzymes.

Dr. Claudia Kaiser (University of Illinois, Chicago) and colleagues studied whether oral pioglitazone (Actos®, Takeda Pharmaceuticals) a drug approved for diabetes that has anti-inflammatory effects was safe to use in people with MS already taking Avonex® (interferon beta-1a, Biogen Idec, Inc.). Secondary goals of the study were to determine the effect on disease activity and brain tissue loss as observed using advanced imaging technology.

Dr. Andrew Goodman (University of Rochester) presented detailed results of a phase 3, placebo-controlled study of oral Fampridine-SR (sustained-release formula of 4-aminopyridine, Acorda Therapeutics) in 301 individuals with all types of MS. Fampridine blocks tiny pores, or potassium channels, on the surface of nerve fibers. This blocking ability may improve the conduction of nerve signals in nerve fibers whose insulating myelin coating has been damaged by MS.

A previously reported six-month, phase 2 controlled study of oral fingolimod (FTY720, Novartis Pharma AG) showed possible benefits in relapse rate and MRI-detected disease activity in relapsing MS, and the drug is now being tested in a larger, phase 3 trial. During the phase 2 study, investigators also measured depression at the beginning of the study and also at 3 months and 6 months into the trial in 239 participants.

To get complete buletin visit
http://www.nationalmssociety.org/site/PageServer?pagename=HOM_RES_research_2007may11_2

Laquinimod (once-day-pill by By Teva)

Teva Moves Ahead on MS Pill

By Robert Steyer
TheStreet.com Staff Reporter
5/1/2007 5:06 PM EDT


Favorable results in a clinical trial for a pill to treat multiple sclerosis has prompted Teva Pharmaceutical Industries (TEVA - Cramer's Take - Stockpickr - Rating) to launch an advanced clinical trial later this year.

Laquinimod is a once-a-day pill developed by Sweden's Active Biotech, which licensed the compound to Teva in mid-2004. Although Teva specializes in generic drugs, it also sells Copaxone for MS and Azilect for Parkinson's disease.

Teva offered mixed results for its test of laquinimod, which was presented at the annual meeting of the American Academy of Neurology in Boston. Teva compared two dosage strengths of its drug -- 0.6 milligrams and 0.3 milligrams -- vs. placebo.

The lower dose showed no statistically significant difference vs. placebo; the higher dose "significantly reduced" MS activity as measured by magnetic resonance imaging, Teva said. The higher dose showed a 38% reduction in the cumulative number of tell-tale lesions in the brain.

FTY720:Aiming to be first once-a-day pill

Preclinical Studies Suggest FTY720 Mechanisms In Multiple Sclerosis May Include Direct Activity In The Brain
Main Category: Multiple Sclerosis News
Article Date: 05 May 2007 - 6:00 PDT


New preclinical data, presented at the American Academy of Neurology (AAN) annual meeting in Boston, reflect the expanding understanding of FTY720's (fingolimod) mechanism of action in multiple sclerosis (MS), suggesting direct beneficial effects in the brain. The data suggest that FTY720 may have the potential to reduce neurodegeneration and enhance repair of the central nervous system (CNS) by modulating S1P receptors expressed on brain cells. Separately, new clinical data presented from the six-month Phase II study found that the proportion of patients with clinical depression was significantly lower in the FTY720 groups compared to placebo.

In the third study, conducted in an established animal model of MS [experimental autoimmune encephalomyelitis (EAE) in rats], researchers found that FTY720 directly administered in the rat brain significantly suppressed the severity of clinical EAE, suggesting additional mechanisms of action independent of lymphocyte depletion. In imaging studies, enhanced myelination and axonal protection associated with the clinical effects were confirmed in animals receiving oral FTY720. (Schubart et al)

http://www.medicalnewstoday.com/medicalnews.php?newsid=69885

Herbs [kalawalla,curcumin, evening primrose,aloe vera]

TURMERIC (HALDI)
It is also said that turmeric can strengthen the blood-brain barrier against attacks that result from auto-immune diseases)[verification needed]. (such as Multiple Sclerosis)
Curry Pharmaceuticals, based in North Carolina, is studying the use of a curcumin cream for psoriasis treatment. Another company is already selling a cream based on curcumin called "Psoria-Gold," which shows anecdotal promise of treating the disease.
Curcumin is thought to be a powerful antinociceptive (pain-relieving) agent. In the November 2006 issue of Arthritis & Rheumatism, a study was published that showed the effectiveness of turmeric in the reduction of joint inflammation, and recommended clinical trials as a possible treatment for the alleviation of arthritis symptoms.[5
Turmeric paste is used by some Indian women to keep them free of superfluous hair.
**Consuming large doses is not recommended in cases of gallstones, obstructive jaundice, acute bilious colic and toxic liver disorders.

ALOE VERA
A. vera has been used externally to treat various skin conditions such as cuts, burns and eczema. It is alleged that sap from Aloe vera eases pain and reduces inflammation. For colon cleansing, constipation and arthritis.
Aloe Vera is a garden succulent well known as the first aid plant. It has been used medicinally since ancient times. It is mentioned in early Egyptian writings as an effective treatment for infections, skin ailments and constipation.

FERN (Polypodium leuctomos) Kalawalla
Kalawalla (Polypodium leucotomos) is a fern which is native to the rain forests of Central and South America. Kalawalla extract has been used for centuries in traditional herbal medicine for the treatment of inflammatory disorders and skin diseases.

While neither Kalawalla nor Rapuani are intended specifically as MS treatments they do have reported benefits.

Kalawalla is sold as a supplement beneficial for sufferers of Vitiligo, a depigmentation condition where there is a genetic effect that makes melanocytes susceptible to injury. Others believe an immune system imbalance may cause the immune system to identify pigments as a foreign substance and therefore destroy it.

The polypodium leucotomos extract is understood to regulate the immune system and restore it to a healthy, strong, balanced position.

A number of MS sufferers have reported improvements after taking this supplement.

Evening Primrose Oil (Gamma-linolenic acid / GLA)
The Evening Primrose plant (Oenothera biennis) contains oil-rich seeds from which Evening Primrose oil is derived. Evening Primrose oil contains 74% linolenic acid (LA) and 8-10% gamma-linolenic acid (GLA). GLA is an Omega-6 essential fatty acid that the body converts to a hormone-like substance called prostaglandin E1 (PGE1). PGE1 keeps blood moving smoothly. When healthy blood flows through the body, inflammation, high blood pressure, and some PMS symptoms are reduced.

In most healthy individuals, the conversion process (omega-6 to GLA to PGE1) happens automatically. However, about 20% of the population cannot convert omega-6 into GLA effectively, and therefore must supplement through diet. The highest quality Evening Primrose oil is extracted without hexane or other chemical solvents. Instead, it is “cold processed”, using the expeller-press method of extraction, which simply squeezes the oil out of the seed without heat.

Flaxseed Oil [Omega3,6,9+Vit.E ]+Vit.C

Flax (also known as Common Flax or Linseed) is a member of the genus Linum in the family Linaceae. The New Zealand flax is unrelated. Flax originated in India and was first domesticated in the Fertile Crescent.[1]


Flax seed oil freshness is an important consideration because rancid oil will have an unpleasant taste and may not be as effective. For this reason it is important to use refrigerated flax seed oil, and oil that contains Vitamin E as a preservative / antioxidant.


Flax Seed Oil (Omega-3 Alpha-Linolenic Acid)

Some MS patients report that supplementing with Omega-3 fatty acid's helps reduce pain and inflammation.

Flax Seed Oil is a rich source of Omega-3 essential fatty acid (EFA). Besides containing Omega-3 EFA’s (specifically Alpha-Linolenic Acid), flax seed oil typically contains approximately 10-20% each of Omega-6 Linoleic Acid (the other primary EFA) and Omega-9. Essential fatty acids are considered "essential" because they are the main structural components of the body's cell membranes, but cannot be synthesized by the body and must be obtained from the diet. Western diets are usually deficient in Omega-3 fatty acids however, and contain too many Omega-6 fatty acids. The ratio of Omega-6's to Omega-3's in the Western diet is believed to be as high as 14:1 (14 grams of Omega 6's for every gram of Omega-3's), whereas a ration of no more than 3:1 is recommended. Excessive amounts of Omega-6 EFA's are believed to promote the development of many diseases, including cardiovascular disease, cancer, and inflammatory and autoimmune diseases. Saturated fats and vegetable oils like corn, soy, safflower and sunflower oil are high in Omega-6 fatty acids, and interfere which the body's ability to utilize Omega-3 EFA’s.

Omega-3 fatty acids are found in certain plants like flax seed, canola oil and walnuts, and in cold water fish such as salmon and tuna. Relying on diet alone for Omega-3’s is difficult though. For instance, contamination is a potential issue when it comes to increasing the amount of fish in one’s diet because fish can accumulate toxins such as mercury, dioxins, and PCBs. And while fish oil contains the most beneficial and active Omega-3 EFA’s - eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - some individuals find that taste and digestive problems are an issue. The main Omega-3 EFA in flax seed oil is alpha-linolenic acid (LNA), which is converted to EPA and DHA in the body, though the rate of conversion probably varies by age, gender, and type of body tissue.

One must also consider the ratio of Omega-6's to Omega-3's in natural food sources. Flax seed oil contains the best ratio (the least Omega-6's to Omega-3's) of any of the vegetarian food sources. Flax seed oil is also one of the richest sources of "lignans", natural phytochemicals that are found in the fiber, rather than the oil portion of flax seeds (depending on their filtration method however, individual flax seed oils may, or may not, contain high lignan levels). Lignans are “phytoestrogens” (structurally related to estrogen) and may protect against chronic diseases, such as hormone-dependent cancers, cardiovascular disease and osteoporosis.



The seeds produce a vegetable oil known as linseed oil or flaxseed oil. It is one of the oldest commercial oils and solvent-processed flax seed oil has been used for centuries as a drying oil in painting and varnishing. Flax seeds come in two basic varieties; brown and yellow (also referred to as golden). Although brown flax can be consumed and has been for thousands of years, it is better known as an ingredient in paints, fibre and cattle feed. Brown and yellow flax have similar nutritional values and equal amounts of short-chain omega-3 fatty acids. The exception is a type of yellow flax called solin which is very low in omega-3 and has a completely different oil profile. A number of studies have shown that people have a very hard time absorbing the Omega-3 from flaxseed oil compared to oily fish (see Fish and plants as a source of Omega-3 for more).

il is most commonly consumed with salads or in capsules. Flax seed owes its nutritional benefits to lignans and omega-3 essential fatty acids. Omega-3s, often in short supply in populations with low-fish diets, promote heart health by reducing cholesterol, blood pressure and plaque formation in arteries.


Surprisingly, flaxseed oil is also useful in controlling constipation. The dietary fiber content in the oil is considerable and helps to ease bowel movements. As it has been known to combat inflammation, it is useful in repairing any intestinal tract damage. It has been known to keep those gallstones at bay and sometimes dissolve existing stones.


Flaxseed oil helps to reduce the severity of nerve damage and also aids in the triggering of nerve impulses. As it nourishes the nerve, it may possibly be of some use in the treating of Parkinson’s disease. It helps to combat the effects of aging and the lignans present in the oil guard against cancer. Sprains and bruises heal faster on the application of flaxseed oil. Another important area where it is of great help is the brain. The omega 3 fatty acids help retain emotional health of a person, helping to tackle depression and possibly Alzheimer’s disease. Used externally, it can soften dry skin. The gel of flaxseed has been used as a poultice on injured areas in many Indian homes.. In fact, rural India has been advocating the use of flaxseed oil for quite a long time.